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In vitro evaluation of stearylamine cationic nanoemulsions for 
improved ocular drug delivery
Oil-in-water nanoemulsions (NEs) represent one of the 
formulation approaches to improve eye-related bio-
availability of lipophilic drugs. The potential of cat-
ionic NEs is pronounced due to the electrostatic inter-
action of positively charged droplets with negatively 
charged mucins present in the tear film, providing 
prolonged formulation residence at the ocular surface. 
The aim of this study was to develop a cationic oph-
thalmic NE with cationic lipid stearylamine (SA) as a 
carrier of a positive charge. The addition of a nonionic 
surfactant provided the dual electro-steric stabiliza-
tion of NEs and enabled tuning of SA concentration to 
achieve an optimal balance between its interaction 
with mucins and biocompatibility. Physicochemical 
characterization, stability profile, in vitro mucoadhe-
sion study and biocompatibility study employing 3D 
HCE-T cell-based model of corneal epithelium pointed 
out the NE with 0.05 % (m/m) SA as the leading formu-
lation. Minimizing SA content while retaining drop-
let/mucin interactions is of great importance for efficacy 
and safety of future ophthalmic drug products.
Keywords: cationic nanoemulsions, stearylamine, 
 ophthalmic drug delivery, biocompatibility, muco-
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Ophthalmic diseases are most commonly treated by topical instillation of eye-drops. 
The conventional eye-drops are quite simple dosage forms and are well accepted by pa-
tients. However, they often raise technical issues, such as solubility, stability and sterility, 
and clinical issues due to short residence time at the ocular surface and consequent low 
bioavailability. A significant number of ophthalmic drugs are lipophilic molecules and it 
is, therefore, challenging to formulate them in the form of conventional eye-drops. Oil-in-
-water (o/w) nanoemulsions (NEs) represent one of the formulation approaches to improve 
ocular bioavailability of lipophilic drugs. Lipophilic drug molecules can be solubilized at 
the innermost oil phase or at the o/w interface of a NE (1) and the nanometric size of the 
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oil droplets gives rise to a large surface area available for drug diffusion (2). It is believed 
that after instillation NE breakdown occurs (due to the composition of tears and blinking) 
which is followed by the release of drug molecules and fusion of the NE oil phase with tear 
film lipid layer (TFLL). Since TFLL has a much slower turnover rate than tears, the unre-
leased drug portion remains in the conjunctival sac for a longer time, acting as a drug 
depot (3). Such NE behavior is especially beneficial for dry eye disease treatment where 
TFLL is often compromised and NEs can replenish not only the aqueous phase, but also 
the lipid phase of the tear film (3). A pilot study on 15 volunteers (5 normal and 10 with dry 
eye symptoms) showed that 4 hours after a single eye-drop instillation of a castor oil NE, 
castor oil could still be detected in tears (4). Furthermore, NE droplet surface can be modi-
fied with cationic lipids or polymers to form positively charged oil droplets. Such cationic 
NEs have the potential to electrostatically bind to negatively charged ocular surface cells 
and mucin chains and hence prolong drug residence (2, 3). Stearylamine (SA) is a cationic 
lipid with surface active properties commonly used to produce positively charged lipo-
somes (5) or emulsions (6–8) and it was found to be safe and well tolerated in rabbits after 
repeated topical ophthalmic administrations (8). Among positively charged polymers chi-
tosan is most commonly used as a NE cationic agent (3), due to its biocompatibility, bio-
degradability and mucoadhesion (9). The choice of ophthalmically acceptable excipients 
(i.e. oils, surfactants, cationic lipids or polymers, isotonizing agent) is of utmost importance 
for successful development of a stable and functional NE formulation rendering the poten-
tial to prolong precorneal residence time and improve bioavailability, which is at the same 
time non-irritant, well-tolerated and comfortable for patients. That is why a deep physico-
chemical characterization (including measurement of droplets size, size distribution, zeta- 
-potential, pH, osmolarity, surface tension and viscosity) and biopharmaceutical charac-
terization (including in vitro mucoadhesion and biocompatibility) are crucial for the 
 success.
The aim of this work was the development of a cationic NE, that could serve as a ve-
hicle for lipophilic ophthalmic drugs. SA was used as a droplet positive charge inducer 
providing the interaction of droplets with the ocular mucins and positively influencing NE 
stability. Nonionic surfactants were selected in order to provide, together with SA, dual 
electro-steric stabilization of NEs, and therefore enable tuning of SA concentration accord-
ing to its interaction with mucins and biocompatibility. Therefore, physicochemical and 
biopharmaceutical characterizations, including in vitro mucoadhesion and biocompatibility, 




For NE preparation the following substances were used: castor oil, virgin (Kemig, 
Croatia), Miglyol® 812 (Kemig), sesame oil, super refined (Croda International Pic, United 
Kingdom), soybean oil, refined (Sigma-Aldrich, Germany), Cremophor® EL (BASF, Germa-
ny), Pluronic® F68 (Sigma-Aldrich), Tween® 60 (Sigma-Aldrich), Tween® 80 (Kemig), glyc-
erol (T.T.T., Croatia) and stearylamine (Sigma-Aldrich). MTT reagent (3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyl tetrazolium bromide) purchased from AppliChem (Germany) was 
623
B. Jurišić Dukovski et al.: In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery, Acta Pharm. 
69 (2019) 621–634.
 
used to determine cell viability in in vitro biocompatibility study. Porcine gastric mucin 
type II (Sigma-Aldrich) was used for in vitro study of mucoadhesion. Hank's balanced salt 
solution (HBSS) pH 7.4 was prepared as an aqueous solution containing: KCl (5.37 mmol L–1), 
NaHCO3 (4.17 mmol L–1), NaCl (136.89 mmol L–1), MgSO4×7H2O (0.41 mmol L–1), d-glucose 
monohydrate (5.55 mmol L–1) (all purchased from Kemig), KH2PO4 (0.44 mmol L–1; Kemika, 
Croatia), Na2HPO4×2H2O (0.34 mmol L–1; Fluka Chemie AG, Switzerland), MgCl2×6H2O 
(0.49 mmol L–1; Merck, Germany), CaCl2×2H2O (1.26 mmol L–1; Sigma-Aldrich) and HEPES 
(30.00 mmol L–1; AppliChem). Simulated tear fluid (STF) pH 7.4 was prepared as an aqueous 
solution containig: KCl (18.78 mmol L–1), NaCl (116.35 mmol L–1), NaHCO3 (26.19 mmol L–1) 
and CaCl2×2H2O (0.54 mmol L–1).
NE preparation
NEs within this work were produced by a high-energy method using microfluidizer 
(Model M-110EH-30, Microfluidics®, USA). NEs without SA were prepared by the addition 
of oil (5 %, m/m) to the aqueous surfactant solution (0.5–5 %, m/m) at room temperature 
under magnetic stirring (Table I). The mixture was then pre-homogenized on Ultra-Tur-
rax® (IKA-Werke GmbH & Company, Germany) during 5 minutes at 6000 rpm and the 
obtained coarse emulsion was further processed on microfluidizer under the pressure of 
1000 bar and 10 cycles. To prepare NEs with SA (SANEs), SA (0.01–0.3 %, m/m) was dis-
solved in Miglyol® 812 (5 %, m/m) by heating to 70 °C. The aqueous solution of Cremophor® 
EL (2.5 %, m/m) and glycerol (2.5 %, m/m) preheated to the same temperature was added to 
the oil phase under magnetic stirring and the rest of the procedure was done as for the NEs 
without SA.
Physicochemical characterization and stability testing
Droplet size, polydispersity index (PDI) and zeta-potential of NEs were measured by 
photon correlation spectroscopy (PCS) using Zetasizer Nano Series (Malvern Instruments, 
United Kingdom) at 25 °C. For that purpose, NE samples were diluted 100´ (V/V) with 
double distilled water (droplet size and PDI) and 10 mM NaCl solution (zeta-potential), 
respectively. pH was measured on a Seven Multi pH/conductometer (Mettler Toledo, USA) 
at 25 °C. NE viscosity was measured using MCR 102 rheometer (Anton Paar, Austria) 
equipped with a cone-plate measuring device (CP 50-1, trim position 102 µm) over a shear 
rate range 1–100 s–1 at 25 °C. The viscosity of oils was determined by employing the same 
method. Surface tension measurements were performed on Krüss K-100C tensiometer 
(Germany), employing the Du Noüy ring method. All measurements were performed at 
25 °C using a water-circulating bath with temperature stability within 0.02 °C. For stability 
testing purposes droplet size, PDI, zeta-potential and pH were measured as described 
after 30 and 150-day storage period at 4 °C.
In vitro biocompatibility study
In vitro biocompatibility study was performed using HCE-T cells (RIKEN Cell Bank, 
Japan). The cells were cultivated as reported previously (11, 12). For in vitro biocompatibility 
studies two types of cell models were employed, namely 2D and 3D HCE-T cell models. 
For cultivations of the 2D model, HCE-T cells suspended in supplemented DMEM/F-12 
624
B. Jurišić Dukovski et al.: In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery, Acta Pharm. 
69 (2019) 621–634.
 
medium were seeded onto a 96-well plate (1×104 cells per well) and grown until reaching 
confluence. The culture medium was then aspirated and the cells were rinsed with HBSS 
(approximately 100 µL per well). The cells were then exposed to NE diluted 10´ (V/V) in 
HBSS, as previously described (13), during 30 minutes at 37 °C. The NE samples were then 
removed, the cells were rinsed with HBSS (approximately 100 µL per well), the culture 
medium was added (100 µL per well) and the cells were left in the incubator until the fol-
lowing day when MTT assay was performed. MTT was dissolved in phosphate buffered 
saline (PBS, Sigma-Aldrich) to obtain a 6 mM solution and 20 µL of such solution were 
added to each well. The cells were then incubated during 3 hours at 37 °C, after which the 
medium was aspirated and 100 µL of isopropanol was added to each well in order to dis-
solve the formazan crystals. The absorbance of the formazan solution was measured at 570 
nm with a microplate reader (1420 Multilabel counter VICTOR3, Perkin Elmer, USA). The 
cells incubated in HBSS were used as a control of 100 % cell viability.
For cultivation of the 3D HCE-T model, Transwell® polycarbonate membrane cell cul-
ture inserts (0.4 mm pore size, 12 mm diameter, surface area 1.12 cm2, Corning B.V. Life 
Sciences, Amsterdam, The Netherlands) were used. The 3D HCE-T model was cultivated 
as reported previously (11, 12). Before treatment with the NE samples, the culture medium 
was aspirated from the basolateral side and the inserts were washed with HBSS. The in-
serts were then transferred to a new 12-well cell culture plate (Corning B.V. Life Sciences) 
and incubated during 30 minutes in HBSS (0.5 mL apical side/1.5 mL basolateral side) at 
37 °C. After incubation, HBSS from the apical side was removed and 0.5 mL of NE sample 
diluted 10 ´ (VV) in HBSS, as previously described (13), was added instead and the model 
was incubated during 30 minutes at 37 °C. After incubation, the test samples were removed 
from the apical side and the inserts were washed with HBSS, after which the inserts were 
transferred to a new 12-well plate with a metal plate containing 2 mL of cell culture medium 
in the basolateral side, while the apical side was exposed to the air-liquid interface (ALI) 
overnight. MTT assay was performed according to the protocol previously reported (11, 
14). Briefly, after removing the cell culture medium, 0.7 mL of MTT solution in the cell 
culture medium (1.2 mM) was added to both apical and basolateral compartment and the 
model was incubated during 3 hours at 37 °C. After removing the MTT solution, formazan 
crystals were dissolved in isopropanol (0.7 mL in both apical and basolateral compart-
ment) and the absorbance was determined as described for 2D HCE-T cell model above.
In vitro mucoadhesion study
For a better understanding of NE interaction with mucin an in vitro study was per-
formed as described by Pereira de Sousa et al. (15) with some modifications. Briefly, 1 % 
(m/m) mucin dispersion in STF was prepared by overnight stirring at room temperature. 
NEs were mixed with the mucin dispersion in 40:7 (V/V) ratio and left under magnetic 
stirring at 300 rpm during 20 minutes at room temperature. Samples were taken at 5 and 
20 minutes and droplet size and zeta-potential were measured as described above.
RESULTS AND DISCUSSION
NE technology has an increasing influence in every aspect of drug delivery (16–18), 
particularly in ophthalmic drug delivery (2, 19). Physicochemical properties affecting in 
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vivo performance of an ophthalmic NE include droplet size, size distribution and zeta-po-
tential, formulation viscosity profile as a function of applied shear, pH, osmolarity, and 
surface tension (20, 21). In order to develop a stable cationic NE with SA as a carrier of 
positive charge, we first performed screening of ophthalmically acceptable oils and non-
ionic surfactants in search for primary formulation with small droplet size and low PDI 
value.
Screening of oils and nonionic surfactants for NE preparation
Four different types of oils (castor oil, Miglyol® 812, sesame oil and soybean oil) and 
surfactants (Cremophor® EL, Pluronic® F68, Tween® 60 and Tween® 80) were used to pro-
duce NEs using microfluidizer (Table I). While the oil concentration was fixed at 5 % (m/m), 
since higher oil concentrations tend to cause blurred vision when NEs are applied to the 
eye (1), the surfactant concentration varied between 0.5 and 5 % (m/m). As can be seen from 
Table I, the oil type had a significant influence on the NE droplet size, which could be  ascribed 
to the difference in the oil viscosity. It was already stated that higher viscosities lead to flow 
resistance in the chamber of a microfluidizer which reduces the rate and efficiency of 
droplet disruption, resulting in larger droplet formation (22). The viscosity values mea-
sured for castor oil, Miglyol® 812, sesame and soybean oil were 704.37 ± 14.85, 22.91 ± 0.05, 
55.89 ± 0.13 and 54.91 ± 0.21 mPa s, respectively. Thus, the largest droplets were obtained 
with castor oil, which had the highest viscosity, and the smallest droplets were produced 
with Miglyol® 812, which had the lowest viscosity. Since smaller oil droplet size contri butes to 
the NE stability and also leads to an increase in the total surface area available for drug 
diffusion (2), Miglyol® 812 was chosen as the oil phase for further studies. While the type 
of nonionic surfactants did not seem to have a strong impact on the droplet size, the increase 
in the surfactant concentration had a significant influence on the droplet size reduction, as 
already reported elsewhere (23, 24). This can be explained by the fact that an excess of 
surfactant in the bulk NE outer phase is available to cover any new droplet surface formed 
during homogenization and by the fact that the droplet surface is covered more rapidly 
(24). Also, lowering the interfacial tension through the use of surfactants may facilitate 
droplet disruption and formation of smaller droplets (25). Zeta-potential of all the NEs 
produced was close to zero or slightly negative, probably due to the preferential adsorption 
of OH– ions on the droplet surface, as explained elsewhere (26). From all the NEs prepared 
the NE formulation with 5 % (m/m) of Miglyol® 812 and 2.5 % (m/m) of Cremophor® EL was 
chosen for further studies because it had the lowest droplet size among the NE formulations 
with PDI value lower than 0.2.
Preparation and physicochemical characterization of cationic stearylamine NEs (SANEs)
After selecting the primary formulation stabilized with nonionic surfactant only, the 
selection of SA concentration for SANE preparation was performed. A total of 4 NE formu-
lations of Miglyol® 812 (5 %, m/m), Cremophor® EL (2.5 %, m/m) and SA (0.01, 0.05, 0.1 and 
0.3 %, m/m) with glycerol as a tonicity agent (2.5 %, m/m) were prepared (Table II) and a 
detailed physicochemical characterization was performed. The obtained SANEs were 
highly fluid and homogenous with milky-white appearance with osmolarity in the physio-
logical range of tear film. All SANE formulations were characterized by small droplet size 
(81.03 to 95.6 nm) and appropriate PDI (0.139 to 0.251) with droplet size and PDI increasing 
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Table I. Droplet size, polydispersity index (PDI) and zeta-potential of nanoemulsions prepared with different 
oil type, surfactant type and surfactant concentration







0.5 374.8 ± 1.6 0.205 ± 0.051 –11.2 ± 0.5
1 281.0 ± 2.8 0.270 ± 0.038 –8.6 ± 0.7
2.5 231.1 ± 3.3 0.448 ± 0.119 –7.2 ± 0.4
5 212.5 ± 2.7 0.419 ± 0.006 –6.7 ± 0.5
Pluronic® F68
0.5 407.6 ± 3.6 0.315 ± 0.054 –12.2 ± 0.9
1 340.9 ± 2.2 0.268 ± 0.058 –9.9 ± 0.9
2.5 258.3 ± 2.5 0.212 ± 0.034 –6.0 ± 0.7
5 223.5 ± 3.9 0.268 ± 0.021 –5.0 ± 0.4
Tween® 60
0.5 458.0 ± 2.8 0.100 ± 0.071 –7.5 ± 0.7
1 380.9 ± 4.2 0.235 ± 0.075 –5.9 ± 0.1
2.5 275.5 ± 3.0 0.238 ± 0.026 –5.5 ± 0.1
5 227.6 ± 4.2 0.323 ± 0.048 –5.0 ± 0.3
Tween® 80
0.5 448.7 ± 11.4 0.250 ± 0.247 –8.6 ± 0.4
1 367.7 ± 3.0 0.274 ± 0.069 –3.1 ± 0.5
2.5 282.0 ± 3.7 0.233 ± 0.018 –2.5 ± 0.6
5 238.5 ± 1.7 0.351 ± 0.069 –2.2 ± 0.2
Miglyol® 812
Cremophor® EL
0.5 205.3 ± 2.1 0.089 ± 0.007 –7.0 ± 0.7
1 158.7 ± 2.5 0.093 ± 0.020 –4.5 ± 0.5
2.5 98.5 ± 0.7 0.160 ± 0.007 –4.3 ± 0.7
5 65.1 ± 0.7 0.216 ± 0.002 –2.2 ± 0.5
Pluronic® F68
0.5 225.5 ± 1.4 0.135 ± 0.019 –1.3 ± 0.3
1 190.8 ± 1.8 0.134 ± 0.008 –1.3 ± 0.5
2.5 137.9 ± 0.7 0.143 ± 0.012 –1.9 ± 0.6
5 95.9 ± 0.6 0.171 ± 0.023 –1.3 ± 0.3
Tween® 60
0.5 197.3 ± 2.4 0.115 ± 0.031 –14.1 ± 0.6
1 160.6 ± 1.4 0.144 ± 0.010 –12.3 ± 0.6
2.5 114.7 ± 1.5 0.289 ± 0.030 –11.0 ± 0.6
5 79.5 ± 0.7 0.348 ± 0.024 –8.2 ± 0.5
Tween® 80
0.5 196.3 ± 1.1 0.131 ± 0.005 –10.7 ± 0.5
1 154.6 ± 1.3 0.184 ± 0.027 –6.0 ± 0.5
2.5 108.5 ± 0.5 0.286 ± 0.020 –2.2 ± 0.6
5 78.2 ± 0.7 0.361 ± 0.046 –1.4 ± 0.8
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0.5 247.6 ± 3.9 0.093 ± 0.039 –2.9 ± 0.6
1 198.5 ± 3.0 0.134 ± 0.016 –2.5 ± 0.4
2.5 132.2 ± 1.9 0.271 ± 0.023 –2.3 ± 0.7
5 92.7 ± 0.8 0.371 ± 0.030 –1.9 ± 0.6
Pluronic® F68
0.5 257.9 ± 4.5 0.140 ± 0.080 –2.2 ± 0.5
1 231.2 ± 4.6 0.114 ± 0.031 –1.9 ± 0.5
2.5 182.2 ± 2.7 0.188 ± 0.030 –1.0 ± 0.2
5 146.6 ± 4.3 0.245 ± 0.113 –0.9 ± 0.9
Tween® 60
0.5 243.1 ± 6.1 0.016 ± 0.016 –5.4 ± 0.5
1 205.4 ± 2.7 0.108 ± 0.052 –7.3 ± 0.6
2.5 143.6 ± 3.9 0.222 ± 0.002 –6.1 ± 0.4
5 86.8 ± 1.8 0.349 ± 0.034 –6.2 ± 0.6
Tween® 80
0.5 233.8 ± 2.7 0.099 ± 0.032 –3.2 ± 0.5
1 193.5 ± 3.2 0.105 ± 0.008 –2.3 ± 0.5
2.5 138.3 ± 2.4 0.199 ± 0.020 –2.9 ± 0.5
5 93.0 ± 2.1 0.340 ± 0.028 –2.7 ± 0.5
Soybean oil
Cremophor® EL
0.5 236.2 ± 3.3 0.148 ± 0.090 –7.1 ± 0.2
1 190.8 ± 3.1 0.097 ± 0.036 –5.2 ± 0.7
2.5 118.4 ± 2.4 0.181 ± 0.019 –4.2 ± 0.8
5 87.8 ± 1.3 0.383 ± 0.011 –3.7 ± 0.3
Pluronic® F68
0.5 253.7 ± 6.3 0.124 ± 0.006 –4.4 ± 0.3
1 229.1 ± 6.2 0.121 ± 0.033 –3.4 ± 0.5
2.5 179.9 ± 4.4 0.050 ± 0.040 –2.8 ± 0.5
5 145.4 ± 2.4 0.212 ± 0.045 –3.6 ± 1.2
Tween® 60
0.5 238.3 ± 3.8 0.127 ± 0.022 –6.4 ± 0.4
1 195.6 ± 2.8 0.167 ± 0.003 –5.2 ± 0.3
2.5 115.3 ± 1.3 0.336 ± 0.039 –5.5 ± 0.4
5 83.8 ± 0.9 0.429 ± 0.049 –5.5 ± 0.3
Tween® 80
0.5 245.1 ± 5.9 0.076 ± 0.055 –9.0 ± 0.3
1 205.9 ± 5.1 0.131 ± 0.021 –4.0 ± 0.6
2.5 149.2 ± 3.8 0.231 ± 0.007 –1.6 ± 0.2
5 99.8 ± 2.4 0.314 ± 0.017 –0.9 ± 0.8
Mean ± SD, n = 2
Table I. Continued
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with the increase of SA concentration (Table II). As expected, zeta-potential also increased 
from 3.1 to 25.5 mV with the SA concentration increase from 0.01 to 0.3 % (m/m). Zeta-po-
tential of droplets influences formulation precorneal residence and stability at the ocular 
surface as well as formulation stability during storage. For all SANE formulations, pH was 
in the range acceptable for ophthalmic administration. SANE formulations behaved as 
Newtonian systems and their viscosity, as determined by rotational rheological characteri-
zation, was in the range similar to the viscosity of water with a slight increase with the 
increase in SA concentration. Low formulation viscosity enables dosing accuracy and ease 
of eye-drop administration. Surface tension is an important physicochemical formulation 
parameter that determines spreading of a formulation across the ocular surface and also 
influences capillary drainage through the nasolacrimal ducts, affecting precorneal resi-
dence time of the instilled formulation (20). As expected, with the increase in cationic 
surfactant concentration, the surface tension of SANE formulation decreased. The surface 
tension of the tear film has a physiological range of 40–46 mN/m (27, 28). Generally, higher 
surface tension values correspond to lower tear film stability, as it is the case in dry eye 
disease, where a surface tension range of 44–53 mN m–1 has been reported (29, 30). The 
surface tension of an ophthalmic formulation should be close to 35 mN m–1, since there are 
indications that the administration of formulations with lower surface tension may be 
painful and uncomfortable (30, 31).
Physical stability of SANE formulations was followed during 150-day storage at 4 °C. 
The formulations did not show any difference in their visual appearance, i.e. no creaming 
or phase separation was observed. The PCS analyses confirmed that during the storage 
period, the droplets stayed in the nanometer range (< 100 nm) with only a minor size in-
crease (~10 nm), no significant changes in droplet size distribution (PDI < 0.25) nor zeta-
potential (Fig. 1), proving therefore a satisfactory formulation stability. As a role of thumb, 
droplet zeta-potential either above 30 mV or below −30 mV is considered a good indicator 
of long-term stability of a charged NE (16). The satisfactory formulation physical stability 
of the investigated SANE formulations, therefore, confirms an effective dual electro-steric 
stabilization. As an indicator of chemical stability, the pH value was also determined. In 
all the formulations a decrease in pH was observed, however, pH values stayed in the 
ophthalmically acceptable range (6.07–8.45).
Table II. Droplet size, polydispersity index (PDI), zeta-potential, pH, viscosity and surface tension of 
nanoemulsions with different stearylamine (SA) concentration








0 81.2 ± 0.4 0.110 ± 0.007 –2.0 ± 0.5 6.76 ± 0.12 1.32 ± 0.01 34.53 ± 1.16
0.01 81.03 ± 0.4 0.139 ± 0.017 3.1 ± 0.5 6.82 ± 0.14 1.40 ± 0.02 34.98 ± 0.38
0.05 86.0 ± 0.4 0.228 ± 0.005 13.2 ± 1.2 7.03 ± 0.12 1.71 ± 0.07 34.57 ± 0.37
0.1 89.9 ± 0.5 0.236 ± 0.005 20.3 ± 1.3 7.78 ± 0.19 3.31 ± 0.32 32.67 ± 0.62
0.3 95.6 ± 2.8 0.251 ± 0.012 25.5 ± 2.15 8.69 ± 0.31 2.80 ± 0.30 31.29 ± 1.02
Mean ± SD, n = 2
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In vitro biocompatibility determination
The most extensively characterized human-derived cell line used in corneal biocom-
patibility and transcorneal permeability studies is the immortalized human corneal epi-
thelial cell line (HCE-T) (11). The majority of in vitro biocompatibility screenings is cur-
rently undertaken using cells cultured in a two-dimensional (2D) environment (32). 
However, this does not accurately reflect the three dimensional (3D) structure of the cor-
neal epithelium. The use of inadequate experimental tools can lead to wrong conclusions 
about formulation biocompatibility. Therefore, SANE formulation biocompatibility was 
screened using both 2D and 3D HCE-T cell-based model. As shown in Fig. 2, cell viability 
in the 2D HCE-T model was severely affected in the presence of formulations, and the 
negative formulation effect on cell viability increased in relation to SA content. However, 
SANE formulations in the same concentration irrespective to SA content were found to be 
biocompatible with the 3D HCE-T cell-based model.
In vitro mucoadhesion determination
Beneficial effects of NEs on eye-related bioavailability will depend on the residence 
time of a formulation at the ocular surface. SA, as a cationic surfactant, has the potential to 
interact with mucins present in the tear fluid. Mucins are high-molecular-mass glycopro-
a)
b)
Fig. 1. a) Droplet size and polydispersity index (PDI), b) zeta-potential of SANE formulations mea-
sured at day 0, 30 and 150. Data are expressed as mean ± SD (n = 2). NE without SA (0 %) is plotted as 
control formulation.
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teins with polysaccharide side chains usually terminated with either fucose or sialic acid, 
which makes them negatively charged at physiological pH (33). In order to determine 
mucoadhesion potential of SANE formulations, we investigated the electrostatic inter-
actions occurring between SANE droplets and diluted mucins by adapting the method 
developed by Bernkop-Schnürch group (15) to mimic the conditions at the ocular surface. 
More precisely, SANE formulations were mixed with 1 % (m/m) mucin dispersion in STF 
in 40:7 (V/V) ratio and the mucin-droplet interaction was followed during 20 minutes (Fig. 
3). This ratio was based on the approximate volumes of an eye-drop (40 µL) and a tear film 
(7 µL) (34, 35). In a short time period after eye-drop instillation, positively charged oil 
droplets should electrostatically interact with negatively charged mucins in order to 
 decrease their clearance from the ocular surface. This droplet/mucin interaction should be 
detectable in vitro by an increase in droplet size and a decrease in droplet zeta-potential. 
This innovative in vitro method for determination of NE mucoadhesive properties was 
used as an alternative to the most frequently used in vitro methods, such as tensile strength 
and rheological method (36). Tensile strength has been the most extensively used in vitro 
method for the determination of bioadhesive interactions and it can be performed on solid 
and semisolid materials or formulations. Besides the need to adjust certain parameters 
(force, contact time and withdrawal speed) depending on the tested sample and consequent 
incomparability of the results obtained among distinct samples (36), this method is not 
appropriate for liquid samples, and was thus not used within this study. Another commonly 
used in vitro method is the rheological method, which can detect interactions between 
mucin and polymers in terms of viscosity increase due to synergism (36, 37). However, due 
to the fact that our NE formulations did not contain any polymeric material, this rheo-
logical method was also not a good choice, since it could underestimate NE mucoadhesive 
properties and give inconsistent and confusing results. The innovative in vitro method 
used within this study is appropriate for liquid samples containing positively charged 
nanomaterial. However, it could not be used to test mucoadhesion of solid or semisolid 
formulations, nor formulations that base their mucoadhesive properties on mechanisms 
other than electrostatic interaction. In vivo studies, that are usually based on measurement 
of formulation residence time on the ocular surface, are needed to confirm the results 
 obtained by in vitro methods, even though such methods do not provide an insight in the 
mucoadhesion mechanism (36).
Fig. 2. 3D (n = 2) and 2D (n = 5) HCE-T model viability (%) determined by MTT assay after 30-minute 
incubation with NE diluted 10 times with HBSS pH 7.4. Cells incubated in HBSS only were used as a 
control of 100 % cell viability. Data are expressed as mean ± SD.
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A drastic change in studied physicochemical parameters was observed immediately 
5 minutes after mixing SANE formulations with mucins (Fig. 3). The droplets reached a 
size above 200 nm for SANE formulations with SA content up to 0.1 %. Interestingly, the 
droplet size increase was not observed for the formulation with the highest SA content. 
Droplet zeta-potential decreased significantly for all SANE formulations. The NE formula-
tion without SA was used as a negative control and no significant change in studied 
physico chemical parameters was observed throughout the whole test period. Therefore, 
the change in size and zeta-potential detected can be ascribed to droplet/mucin interaction 
mediated by SA positively charged groups at the droplet interface.
CONCLUSIONS
Physicochemical parameters (droplet size < 100 nm, PDI < 0.25, zeta-potential ~13 mV, 
pH ~7, surface tension ~35 mN m–1) and stability profile pointed out SANE formulation 
with 0.05 % SA as the leading formulation. This was confirmed in in vitro mucoadhesion 
study where substantial droplet/mucin interaction was determined for the mentioned 
SANE formulation. The selected formulation was also found to be biocompatible with the 
3D HCE-T cell-based model of corneal epithelium. Minimizing SA content while retaining 




Fig. 3. a) Droplet size and b) zeta-potential of nanoemulsions measured before and 5 and 20 minutes 
after mixing with 1 % (m/m) mucin dispersion in STF in 40:7 (V/V) ratio. NE without SA (0 %) was used 
as control formulation. Data are expressed as mean ± SD.
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